Literature DB >> 12480308

Applying peptide antigens onto bare skin: induction of humoral and cellular immune responses and potential for vaccination.

Charalambos D Partidos1, Anne-Sophie Beignon, Fred Brown, Ed Kramer, Jean-Paul Briand, Sylviane Muller.   

Abstract

The development of non-invasive immunisation procedures is a top priority for public health agencies when it is realised that the current immunisation practices are unsafe, particularly in developing countries due to the widespread reuse of non-sterile syringes. There is a risk of abscess formation resulting in impairment of meat quality or the value of the hide, and the risk of transmission of infectious diseases when vaccines are administered to food animals by injection. Recently, the skin has emerged as an alternative route for non-invasive delivery of vaccines. Topical application of various types of antigens (mainly proteins and toxoids) with an adjuvant resulted in the induction of systemic and mucosal immune responses. However, due to skin barrier constraints and the physicochemical properties of large molecular weight proteins, the immune responses are variable and require further optimisation. Small molecular size synthetic peptides when applied onto bare skin with an adjuvant are effective immunogens, inducing both humoral and cellular immune responses. Their use as vaccines offers considerable advantages over conventional preparations in terms of safety, purity, stability, availability and cost. Therefore, they could be the most suitable candidate immunogens for skin immunisation. This review describes our recent observations on the immunogenicity of synthetic peptides applied onto bare skin in relation to vaccination.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12480308     DOI: 10.1016/s0168-3659(02)00268-7

Source DB:  PubMed          Journal:  J Control Release        ISSN: 0168-3659            Impact factor:   9.776


  4 in total

1.  Skin localization of cow's milk proteins delivered by a new ready-to-use atopy patch test.

Authors:  D Soury; G Barratt; S Ah-Leung; P Legrand; H Chacun; G Ponchel
Journal:  Pharm Res       Date:  2005-08-24       Impact factor: 4.200

2.  Human skin permeation of emerging mycotoxins (beauvericin and enniatins).

Authors:  Lien Taevernier; Lieselotte Veryser; Nathalie Roche; Kathelijne Peremans; Christian Burvenich; Catherine Delesalle; Bart De Spiegeleer
Journal:  J Expo Sci Environ Epidemiol       Date:  2015-03-11       Impact factor: 5.563

3.  Immunogenicity in humans of a transdermal multipeptide melanoma vaccine administered with or without a TLR7 agonist.

Authors:  Max O Meneveau; Gina R Petroni; Elise P Salerno; Kevin T Lynch; Mark Smolkin; Elizabeth Woodson; Kimberly A Chianese-Bullock; Walter C Olson; Donna Deacon; James W Patterson; William W Grosh; Craig L Slingluff
Journal:  J Immunother Cancer       Date:  2021-05       Impact factor: 13.751

Review 4.  Transcutaneous antigen delivery system.

Authors:  Mi-Young Lee; Meong-Cheol Shin; Victor C Yang
Journal:  BMB Rep       Date:  2013-01       Impact factor: 4.778

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.